Targeting extracellular DNA to deliver IGF-1 to the injured heart

Sci Rep. 2014 Mar 7:4:4257. doi: 10.1038/srep04257.

Abstract

There is a great need for the development of therapeutic strategies that can target biomolecules to damaged myocardium. Necrosis of myocardium during a myocardial infarction (MI) is characterized by extracellular release of DNA, which can serve as a potential target for ischemic tissue. Hoechst, a histological stain that binds to double-stranded DNA can be conjugated to a variety of molecules. Insulin-like growth factor-1 (IGF-1), a small protein/polypeptide with a short circulating-half life is cardioprotective following MI but its clinical use is limited by poor delivery, as intra-myocardial injections have poor retention and chronic systemic presence has adverse side effects. Here, we present a novel delivery vehicle for IGF-1, via its conjugation to Hoechst for targeting infarcted tissue. Using a mouse model of ischemia-reperfusion, we demonstrate that intravenous delivery of Hoechst-IGF-1 results in activation of Akt, a downstream target of IGF-1 and protects from cardiac fibrosis and dysfunction following MI.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • DNA / metabolism*
  • Disease Models, Animal
  • Extracellular Space / metabolism
  • Fibrosis
  • Humans
  • Insulin-Like Growth Factor I / administration & dosage*
  • Insulin-Like Growth Factor I / chemistry
  • Macrophages / metabolism
  • Male
  • Mice
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / genetics*
  • Myocardial Infarction / metabolism*
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / pathology
  • Myocytes, Cardiac / metabolism
  • Protein Binding
  • Protein Transport

Substances

  • Insulin-Like Growth Factor I
  • DNA